慢性阻塞性肺疾病患者血清CTRP-9水平及其临床意义
|
摘要
目的探讨慢性阻塞性肺疾病(COPD)患者血清C1q肿瘤坏死因子相关蛋白9(CTRP-9)水平及其临床意义。方法选取2016年10月—2017年10月罗定市人民医院就诊的90例COPD稳定期患者作为观察组,另选取同期于该院体检的90例健康居民作为对照组。分别采集两组血浆标本,应用酶联免疫吸附试验法测定两组血清CTRP-9水平,采用肺功能仪测量两组第1秒用力呼气容积占预计值百分比(FEV1%pred),并分析两组评价指标的相关性。结果观察组血清CTRP-9水平高于对照组(P<0.05);观察组FEV1%pred低于对照组(P<0.05);Pearson相关性分析结果显示,观察组血清CTRP-9水平与患者肺功能指标FEV1%pred呈负相关(r=-0.803,P=0.004)。结论 CTRP-9在COPD患者血清中呈高表达,且其表达水平与患者肺功能存在相关性。
Objective To investigate the serum level of C1 q tumor necrosis factor-related protein 9(CTRP-9) in patients with chronic obstructive pulmonary disease and its clinical significance. Methods A total of 90 stable patients with chronic obstructive pulmonary disease who were present in our hospital from October 2016 to October 2017 were selected as the observation group. In the same period, 90 healthy residents who were physically examined in our hospital were selected as the control group. The serum levels of CTRP-9 were determined by enzyme-linked immunosorbent assay. Forced expiratory volume in 1 st second as percentage of predicted values(FEV1%pred) of two groups were measured by spirometer, and analyzed with the serum levels of CTRP-9 for their correlation. Results The serum CTRP-9 level in the observation group was significantly higher than that in the control group(P < 0.05). The FEV1%pred of the observation group was significantly lower than that of the control group(P < 0.05). The results of the Person correlation analysis showed that the serum level of CTRP-9 was negatively correlated with FEV1%pred(r =-0.803, P = 0.004). Conclusions CTRP-9 is highly expressed in the serum of patients with chronic obstructive pulmonary disease, and the level of its expression is correlated with lung function of patients.
Objective To investigate the serum level of C1 q tumor necrosis factor-related protein 9(CTRP-9) in patients with chronic obstructive pulmonary disease and its clinical significance. Methods A total of 90 stable patients with chronic obstructive pulmonary disease who were present in our hospital from October 2016 to October 2017 were selected as the observation group. In the same period, 90 healthy residents who were physically examined in our hospital were selected as the control group. The serum levels of CTRP-9 were determined by enzyme-linked immunosorbent assay. Forced expiratory volume in 1 st second as percentage of predicted values(FEV1%pred) of two groups were measured by spirometer, and analyzed with the serum levels of CTRP-9 for their correlation. Results The serum CTRP-9 level in the observation group was significantly higher than that in the control group(P < 0.05). The FEV1%pred of the observation group was significantly lower than that of the control group(P < 0.05). The results of the Person correlation analysis showed that the serum level of CTRP-9 was negatively correlated with FEV1%pred(r =-0.803, P = 0.004). Conclusions CTRP-9 is highly expressed in the serum of patients with chronic obstructive pulmonary disease, and the level of its expression is correlated with lung function of patients.
引文
[1]王蕾,杨汀,王辰.2017年版慢性阻塞性肺疾病诊断,处理和预防全球策略解读[J].中国临床医生杂志,2017,45(1):104-108.
[2]周秩峤,徐何,杨威.血清FKN,IL-8和IL-17水平与慢性阻塞性肺疾病肺功能的关系[J].海南医学,2016,27(14):2349-2351.
[3]谭金锋,张若溪,于波,等.阿托伐他汀对ACS患者血清CTRP9的影响及其机制的研究[J].中国心血管病研究,2016,14(9):822-826.
[4]金巧艳,曾明华,谭延振,等.CTRP9抑制低氧环境下肺微血管内皮细胞IL-6和TNF-α表达的研究[J].心脏杂志,2017,9(4):399-404.
[5]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].全科医学临床与教育,2013,36(5):484-491.
[6]蔡柏蔷.慢性阻塞性肺疾病诊断,处理和预防全球策略(2017GOLD报告)解读[J].国际呼吸杂志,2017,37(1):6-17.
[7]丁宁,王胜.慢性阻塞性肺疾病发病机制最新研究进展[J].临床肺科杂志,2016(1):133-136.
[8]李有霞,郑则广,刘妮,等.慢性阻塞性肺疾病急性加重伴肺动脉栓塞的危险因素分析[J].中华结核和呼吸杂志,2016,39(4):298-303.
[9]雷虹,张洁,王瑾瑜,等.补体C1q/肿瘤坏死因子相关蛋白家族研究进展[J].生理科学进展,2015,21(1):43-48.
[10]张君,李军,张东霞,等.血清Hs-CRP及CTRP9与冠脉支架介入术后再狭窄的相关性研究[J].川北医学院学报,2017,15(6):926-929.
[11]KAMBARA T,SHIBATA R,OHASHI K,et al.C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism[J].Molecular&Cellular Biology,2015,35(12):2173-2185.
[12]杨瑞,张存娟,邢文娟,等.脂肪因子CTRP9对低氧性肺动脉高压大鼠肺血管的舒张作用及其机制[J].心脏杂志,2016,13(1):1-6.
[13]刘翠翠,赵龙,石晓岚,等.CTRP9抑制幼年哮喘小鼠气道平滑肌细胞增殖和炎性反应的研究[J].中国儿童保健杂志,2017,25(4):361-364.
[14]林佳乐,侯静波.C1q/肿瘤坏死因子相关蛋白9与心血管疾病关系的研究进展[J].心肺血管病杂志,2016,35(7):588-590.
[15]韦海燕,孙印,何士杰,等.慢性阻塞性肺疾病稳定期患者血清CTRP-4,CTRP-5水平变化及意义[J].山东医药,2017,57(45):87-89.
[2]周秩峤,徐何,杨威.血清FKN,IL-8和IL-17水平与慢性阻塞性肺疾病肺功能的关系[J].海南医学,2016,27(14):2349-2351.
[3]谭金锋,张若溪,于波,等.阿托伐他汀对ACS患者血清CTRP9的影响及其机制的研究[J].中国心血管病研究,2016,14(9):822-826.
[4]金巧艳,曾明华,谭延振,等.CTRP9抑制低氧环境下肺微血管内皮细胞IL-6和TNF-α表达的研究[J].心脏杂志,2017,9(4):399-404.
[5]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].全科医学临床与教育,2013,36(5):484-491.
[6]蔡柏蔷.慢性阻塞性肺疾病诊断,处理和预防全球策略(2017GOLD报告)解读[J].国际呼吸杂志,2017,37(1):6-17.
[7]丁宁,王胜.慢性阻塞性肺疾病发病机制最新研究进展[J].临床肺科杂志,2016(1):133-136.
[8]李有霞,郑则广,刘妮,等.慢性阻塞性肺疾病急性加重伴肺动脉栓塞的危险因素分析[J].中华结核和呼吸杂志,2016,39(4):298-303.
[9]雷虹,张洁,王瑾瑜,等.补体C1q/肿瘤坏死因子相关蛋白家族研究进展[J].生理科学进展,2015,21(1):43-48.
[10]张君,李军,张东霞,等.血清Hs-CRP及CTRP9与冠脉支架介入术后再狭窄的相关性研究[J].川北医学院学报,2017,15(6):926-929.
[11]KAMBARA T,SHIBATA R,OHASHI K,et al.C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism[J].Molecular&Cellular Biology,2015,35(12):2173-2185.
[12]杨瑞,张存娟,邢文娟,等.脂肪因子CTRP9对低氧性肺动脉高压大鼠肺血管的舒张作用及其机制[J].心脏杂志,2016,13(1):1-6.
[13]刘翠翠,赵龙,石晓岚,等.CTRP9抑制幼年哮喘小鼠气道平滑肌细胞增殖和炎性反应的研究[J].中国儿童保健杂志,2017,25(4):361-364.
[14]林佳乐,侯静波.C1q/肿瘤坏死因子相关蛋白9与心血管疾病关系的研究进展[J].心肺血管病杂志,2016,35(7):588-590.
[15]韦海燕,孙印,何士杰,等.慢性阻塞性肺疾病稳定期患者血清CTRP-4,CTRP-5水平变化及意义[J].山东医药,2017,57(45):87-89.